top of page
Sage is attending BioEurope Spring in Lisbon from March 23-25, 2026! Please click here to meet!
Menu
Close
Sage
Why Sage?
What Sage Is
What Makes Sage Different?
Our Platform
About Sage
How We Work
Services
M & A
Licensing
Track Record
Locations
Added Value
Sage Clients
Testimonials
SAGEIQ
Sage Global
Sage APAC
Sage China
Sage Japan
Sage India
Team
News
Media
Downloads
Sage 2025 Review
Meet Us!
Contact
Latest News
GLOBAL BIOSCIENCES DEALMAKERS: 30+ YEARS. 300+ CLIENTS & DEALS. BILLIONS IN VALUE.
Sage
Why Sage?
What Sage Is
What Makes Sage Different?
Our Platform
About Sage
How We Work
Services
M & A
Licensing
Track Record
Locations
Added Value
Sage Clients
Testimonials
SAGEIQ
Sage Global
Sage APAC
Sage China
Sage Japan
Sage India
Team
News
Media
Downloads
Sage 2025 Review
Meet Us!
Contact
More
Use tab to navigate through the menu items.
Sage Group News
Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells
Zumutor Biologics is a biotechnology company based in Boston, USA, and Bangalore, India, focused on advancing innovative cancer...
D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner
Our client, PolyPid Ltd. ( PolyPid - Optimized Therapeutics ; NASDAQ:PYPD) has a patented surgical site infection (SSI) prevention...
Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification
Evecxia deploys 5-hydroxytryptophan, 5-HTP, to achieve Serotonin Synthesis Amplification. 5-HTP amplifies brain serotonin and have shown...
bottom of page
